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Background: Hydroxy-methylglutaryl (HMG) CoA reductase inhibitors or statins are the most effective medications for reducing elevated 
concentrations of low-density lipoprotein cholesterol (LDL-C). Many clinicians believe that statins increase muscle pain, but this has not been 
observed in controlled clinical trials and the effect of statins on muscle performance has not been carefully examined. 
Methods: The Effect of STatins On Skeletal Muscle Function and Performance (STOMP; NCT00609063) study administered atorvastatin 80 mg 
daily (ATOR: n=202 with 103 women; age 43 ± 16 yrs) or placebo (PL: n=217 with 113 women; age 45 ± 16 yrs) to healthy, statin-naive subjects for 
6 months or until subjects met the study definition of myalgia (new and unexplained muscle pain on study drug that abated with dechallenge and 
reoccurred upon rechallenge). Blood lipids, creatine kinase (CK), alanine aminotransferase (ALT), and muscle strength (handgrip, elbow and knee 
isometric and isokinetic strength, knee endurance) were measured at baseline and again after completing drug treatment. 
Results: Compliance to drug treatment did not differ (p = 0.44) between groups (ATOR: 94.5 ± 7.0% vs. PL: 93.9 ± 8.2 % compliance). LDL-C 
decreased (p< 0.01) by 59.1 ± 31.7 mg/dL in ATOR subjects with no change in PL subjects. CK and ALT increased (both p < 0.01) in ATOR subjects 
by 20.8 ± 141.1 and 15.7 ± 27.5 U/L, respectively, with no change in PL subjects (ΔCK: 1.5 ± 167.6 U/L and ΔALT: 3.2 ± 24.3 U/L). There were 
no significant changes in muscle strength or aerobic performance with ATOR vs. PL (all p > 0.19). Nineteen ATOR subjects and 10 PL subjects met 
the study definition for myalgia (X2 = 3.74; p = 0.05). The myalgic ATOR subjects exhibited muscle strength declines in 10 of 16 measured variables 
whereas the myalgic PL subjects exhibited strength declines in 4 of 16 variables (X2 = 4.6; p = 0.03). 
Conclusion: These results from a blinded controlled trial confirm the clinical impression that statins increase muscle symptoms in previously 
untreated subjects. Moreover, statin-associated myalgia appears to induce skeletal muscle strength declines that could exacerbate existing disease 
pathologies and compromise quality of life. 
